Results 1 to 10 of about 823 (105)

Effects of PPARα, PPARγ, and dual PPARα/γ agonists on liver tissue and biochemical markers in NAFLD-induced Wistar rats [PDF]

Research in Pharmaceutical Sciences
Background and purpose: Non-alcoholic fatty liver disease (NAFLD) is the most common liver-related metabolic disorder worldwide, affecting approximately 25% of the global population.
Elham Khoshbakht, Negar Dinarvand, Hamid Yaghooti, Behrouz Taheri, Narges Mohammadtaghvaei   +4 more
doaj   +2 more sources

Efficacy of Dapagliflozin vs. Saroglitazar on Hepatic Steatosis and Fibrosis in Patients of Type 2 Diabetes Mellitus and Metabolic-Associated Steatotic Liver Disease (MASLD) [PDF]

Indian Journal of Endocrinology and Metabolism
Introduction: There is a rising prevalence of metabolic-associated steatotic liver disease (MASLD), particularly in patients with type 2 diabetes mellitus, which needs early detection and treatment to prevent the grave outcomes.
Bijay K. Das, Sambit Das, Dayanidhi Meher, Arun K. Choudhury, Sourav Padhee, Sandeep K. Sahu, Devadarshini Sahoo, Binod Prusty, Vishal Agarwal   +8 more
doaj   +2 more sources

Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience

JGH Open, 2023
Background and Aim Saroglitazar, a dual PPAR α/γ agonist, is useful in management of NAFLD and diabetic dyslipidemia. Here, we report the safety and efficacy of saroglitazar in NAFLD patients with or without diabetes including compensated cirrhosis ...
Sujit Chaudhuri
exaly   +2 more sources

Efficacy and safety of SarogLItazar as an add-on medication to Metformin and lifestyle intervention in women with PolyCystic Ovary Syndrome (SLIM-PCOS trial): study protocol for a randomized, open-label, parallel group clinical trial [PDF]

Trials
Background Emerging concepts on the role of insulin resistance (IR) in the pathogenesis of polycystic ovary syndrome (PCOS) have driven a shift in the therapeutic approach towards interventions targeting IR.
Niti Mittal, Savita Singhal, Rakesh Mittal   +2 more
doaj   +2 more sources

The new era of MASH pharmacotherapy: a comprehensive review of FDA-approved and emerging agents [PDF]

Frontiers in Gastroenterology
BackgroundMetabolic dysfunction-associated steatohepatitis (MASH), formerly nonalcoholic steatohepatitis (NASH), is a progressive liver disease and a leading cause of cirrhosis and liver-related mortality worldwide, affecting approximately 3%–5% of the ...
Abeer Qasim, Rayan Alataa, Fnu Veena, Elona Shehi   +3 more
doaj   +2 more sources

Saroglitazar may reduce the requirement of insulin dose during the treatment of diabetic dyslipidemia

IHJ Cardiovascular Case Reports (CVCR), 2017
This is a case report of 78 years old lady with uncontrolled type 2 diabetes and dyslipidemia. Patient was also suffering from impaired renal function with serum creatinine of 1.7 mg/dL.
Amitesh Kumar Chatterjee
exaly   +3 more sources

Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients

Indian Heart Journal, 2015
Saroglitazar is a dual PPAR α/γ agonist approved in India for the management of diabetic dyslipidemia. Aims: The objective of this study was to evaluate the safety and efficacy of saroglitazar 4 mg once daily in clinical practice.
Kamal Sharma, Rajwanth Mathur
exaly   +3 more sources

Saroglitazar Ameliorates Pulmonary Fibrosis Progression in Mice by Suppressing NF-κB Activation and Attenuating Macrophage M1 Polarization [PDF]

Medicina
Background and Objectives: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease with limited therapeutic options.
Yawen Zhang, Jiaquan Lin, Xiaodong Han, Xiang Chen   +3 more
doaj   +2 more sources

Saroglitazar Mitigated Cyclophosphamide-Induced Testicular Injury: Crosstalk Between Oxidative Stress, Inflammation and Apoptosis [PDF]

Pharmaceuticals
Background: Cyclophosphamide (CYC) is an effective chemotherapeutic agent and immunosuppressant drug. Former research showed that CYC induces testicular toxicity through oxidative stress, inflammation and apoptosis.
Bandar H. Alanazi, Omnia A. Nour, Marwa S. Serrya   +2 more
doaj   +2 more sources

Effectiveness of Saroglitazar in MASLD Patients: A Prospective, Real‐World Assessment of Liver and Metabolic Health [PDF]

Endocrinology, Diabetes & Metabolism
Background Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) is a significant health concern and is commonly associated with conditions such as dyslipidemia, insulin resistance, and increased risk of cardiovascular disease.
Mukulesh Gupta, Harshita Lachhwani, Kumar Praful Chandra, Rajiv Awasthi, Dinesh Kumar   +4 more
doaj   +2 more sources